Antibody Programs (Malaria)
Malaria
Pre-clinicalActive
Key Facts
About Ibex Biosciences
Ibex Biosciences is a private, pre-clinical biotech firm pursuing a multi-platform strategy in antibodies, gene therapy, and regenerative medicine. The company leverages its internal discovery capabilities, highlighted by its CSO's background in phage display technology, to build a wholly-owned pipeline targeting oncology, infectious disease, and inflammatory conditions. Currently in a pre-revenue stage, Ibex is actively seeking investment through a Regulation D 506(c) offering to advance its programs. Its management team brings decades of experience in preclinical research, gene therapy, and business development.
View full company profileTherapeutic Areas
Other Malaria Drugs
| Drug | Company | Phase |
|---|---|---|
| Chloroquine Phosphate | Ipca Laboratories | Commercial |
| Malaria Vaccine (R21/Matrix-M) | Novavax | Phase 3 |
| Anti-malarial Portfolio | Strides Pharma | Approved |
| STANDARD Q Malaria Pf/Pan Ag Test | SD BioSensor | Approved |
| Anti-malarial Portfolio (ACTs) | Bliss GVS Pharma | Approved |
| Malaria Vaccine | VLP Biotech | Pre-clinical |
| Malaria-on-a-Chip Model | Hesperos | Pre-clinical |
| Malaria Antibodies | new/era/mabs | Research/Pre-clinical |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| Malaria | Keltic Pharma Therapeutics | Pre-clinical |
| Malaria RDTs | Access Bio | Commercial |
| Malaria Nanobody | VicuTec Biologicals | Pre-clinical |